Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evobrutinib - Merck Serono

X
Drug Profile

Evobrutinib - Merck Serono

Alternative Names: M-2951; MSC-2364447; MSC2364447C

Latest Information Update: 14 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Serono
  • Developer EMD Serono; Merck Serono
  • Class Amines; Anti-inflammatories; Antirheumatics; Phenyl ethers; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • No development reported Encephalomyelitis
  • Discontinued Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 29 Apr 2024 EMD Serono and Merck terminate the phase III evolutionRMS 1 trial in Multiple sclerosis in USA, Ukraine, United Kingdom, Taiwan, Spain, Serbia, Russia, Poland, Netherlands, South Korea, Mexico, Italy, Israel, India, Hungary, Hong Kong, Germany, Georgia, France, Finland, Estonia, Croatia, Czech Republic, Colombia, Canada, Bulgaria, Bosnia-Herzegovina, Belgium, Australia, Austria, Argentina (PO), due to the results of EVOLUTION clinical trials, which showed that evobrutinib did not meet its primary endpoint (NCT04338022) (EudraCT2019-004972-20)
  • 26 Apr 2024 EMD Serono and Merck terminate a phase II trial in Multiple sclerosis in Ukraine, Serbia, Russia, Poland, Bulgaria, Ukraine, Spain, Solvakia and Czech Republic (PO), due to the results of EVOLUTION clinical trials, which showed that evobrutinib did not meet its primary endpoint (NCT02975349) (EudraCT2016-001448-21)
  • 19 Mar 2024 Merck terminates phase-III evolutionRMS 2 trial in Multiple sclerosis (Treatment-experienced) in USA, Belarus, Brazil, Bulgaria, Canada, France, Germany, Greece, India, Italy, Latvia, Lithuania, Malaysia, Moldova, Norway, Philippines, Poland, Portugal, Puerto Rico , Romania, Russia, Saudi Arabia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Thailand, Turkey, Ukraine (PO) due to evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies (NCT04338061)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top